泌尿外科指南

订阅

MedSci主页 / 所有栏目 / 泌尿外科指南

2021 HKGS/HKUA共识：在多病共存和多重用药时代男性下尿路症状的个体化治疗

2021-04-20 香港老年科医学会 Hong Kong Med J.2021 Apr;27(2):127-139.

下尿路症状

2021年4月，香港老年科医学会(HKGS)联合香港泌尿外科协会(HKUA)共同发布了在多病共存和多重用药时代男性下尿路症状的个体化治疗共识。香港老人科医学会和香港泌尿外科学会的成员组成工作小组，审核

中文标题：

2021 HKGS/HKUA共识：在多病共存和多重用药时代男性下尿路症状的个体化治疗

英文标题：

Hong Kong Geriatrics Society and Hong Kong Urological Association consensus on personalised management of male lower urinary tract symptoms in the era of multiple co-morbidities and polypharmacy

发布机构：

香港老年科医学会

发布日期：

2021-04-20

简要介绍：

2021年4月，香港老年科医学会(HKGS)联合香港泌尿外科协会(HKUA)共同发布了在多病共存和多重用药时代男性下尿路症状的个体化治疗共识。香港老人科医学会和香港泌尿外科学会的成员组成工作小组，审核下尿路症状的诊断和医学治疗证据。两会就有关下尿路症状男性患者的护理流程，以及在基层医疗机构中使用尿路选择性α受体阻滞剂、抗毒蕈碱药、β-3肾上腺素受体激动剂和5α-还原酶抑制剂达成共识。这份共识为下尿路症状男性患者提供新的治疗范例。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 HKGS_HKUA共识：在多病共存和多重用药时代男性下尿路症状的个体化治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e378c1c002091ec3, title=2021 HKGS/HKUA共识：在多病共存和多重用药时代男性下尿路症状的个体化治疗, enTitle=Hong Kong Geriatrics Society and Hong Kong Urological Association consensus on personalised management of male lower urinary tract symptoms in the era of multiple co-morbidities and polypharmacy, guiderFrom=Hong Kong Med J.2021 Apr;27(2):127-139., authorId=0, author=, summary=2021年4月，香港老年科医学会(HKGS)联合香港泌尿外科协会(HKUA)共同发布了在多病共存和多重用药时代男性下尿路症状的个体化治疗共识。香港老人科医学会和香港泌尿外科学会的成员组成工作小组，审核, cover=https://img.medsci.cn/2021430/1619716691442_2020535.jpg, journalId=0, articlesId=null, associationId=1530, associationName=香港老年科医学会, associationIntro=, copyright=0, guiderPublishedTime=Tue Apr 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年4月，香港老年科医学会(HKGS)联合香港泌尿外科协会(HKUA)共同发布了在多病共存和多重用药时代男性下尿路症状的个体化治疗共识。香港老人科医学会和香港泌尿外科学会的成员组成工作小组，审核下尿路症状的诊断和医学治疗证据。两会就有关下尿路症状男性患者的护理流程，以及在基层医疗机构中使用尿路选择性&alpha;受体阻滞剂、抗毒蕈碱药、&beta;-3肾上腺素受体激动剂和5&alpha;-还原酶抑制剂达成共识。这份共识为下尿路症状男性患者提供新的治疗范例。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=33613, tagName=下尿路症状)], categoryList=[CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=82055, guiderKeyword=男性下尿路症状, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7512, appHits=44, showAppHits=0, pcHits=364, showPcHits=7468, likes=0, shares=5, comments=5, approvalStatus=1, publishedTime=Fri Apr 30 01:23:50 CST 2021, publishedTimeString=2021-04-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Apr 30 01:18:19 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 05:01:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 HKGS_HKUA共识：在多病共存和多重用药时代男性下尿路症状的个体化治疗.pdf)])
2021 HKGS_HKUA共识：在多病共存和多重用药时代男性下尿路症状的个体化治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2143782, encodeId=674d2143e828b, content=- ̗̀(๑ᵔ⌔ᵔ๑), beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/18/746d2af7eef34775c366eb09b720f6d2.jpg, createdBy=88032117766, createdName=小小硕, createdTime=Tue Jun 20 00:10:50 CST 2023, time=2023-06-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=964056, encodeId=9f5b96405639, content=转及格分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:02:38 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963839, encodeId=3f6596383902, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:06:49 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961712, encodeId=2f9f961e12f7, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6012201890, createdName=120b82d8m06暂无昵称, createdTime=Fri Apr 30 06:53:38 CST 2021, time=2021-04-30, status=1, ipAttribution=)]
    2023-06-20 小小硕 来自广东省

    - ̗̀(๑ᵔ⌔ᵔ๑)

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2143782, encodeId=674d2143e828b, content=- ̗̀(๑ᵔ⌔ᵔ๑), beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/18/746d2af7eef34775c366eb09b720f6d2.jpg, createdBy=88032117766, createdName=小小硕, createdTime=Tue Jun 20 00:10:50 CST 2023, time=2023-06-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=964056, encodeId=9f5b96405639, content=转及格分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:02:38 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963839, encodeId=3f6596383902, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:06:49 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961712, encodeId=2f9f961e12f7, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6012201890, createdName=120b82d8m06暂无昵称, createdTime=Fri Apr 30 06:53:38 CST 2021, time=2021-04-30, status=1, ipAttribution=)]
    2021-05-09 忻雨

    转及格分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2143782, encodeId=674d2143e828b, content=- ̗̀(๑ᵔ⌔ᵔ๑), beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/18/746d2af7eef34775c366eb09b720f6d2.jpg, createdBy=88032117766, createdName=小小硕, createdTime=Tue Jun 20 00:10:50 CST 2023, time=2023-06-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=964056, encodeId=9f5b96405639, content=转及格分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:02:38 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963839, encodeId=3f6596383902, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:06:49 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961712, encodeId=2f9f961e12f7, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6012201890, createdName=120b82d8m06暂无昵称, createdTime=Fri Apr 30 06:53:38 CST 2021, time=2021-04-30, status=1, ipAttribution=)]
    2021-05-09 忻雨

    不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2143782, encodeId=674d2143e828b, content=- ̗̀(๑ᵔ⌔ᵔ๑), beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/18/746d2af7eef34775c366eb09b720f6d2.jpg, createdBy=88032117766, createdName=小小硕, createdTime=Tue Jun 20 00:10:50 CST 2023, time=2023-06-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=964056, encodeId=9f5b96405639, content=转及格分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:02:38 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963839, encodeId=3f6596383902, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:06:49 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961712, encodeId=2f9f961e12f7, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6012201890, createdName=120b82d8m06暂无昵称, createdTime=Fri Apr 30 06:53:38 CST 2021, time=2021-04-30, status=1, ipAttribution=)]
    2021-04-30 120b82d8m06暂无昵称

    特别好

    0

相关指南

女性下尿路症状临床指南（第二版）

日本泌尿外科协会(JUA,Japanese Urological Association) · 2021-03-01

2019 SIR多学科立场声明：前列腺动脉栓塞治疗良性前列腺增生引起的下尿路症状

介入放射学会(SIR,Society of Interventional Radiology) · 2019-03-26

2018 AUA指南：良性前列腺增生引起的下尿路症状的手术管理

美国泌尿外科学会(AUA,American Urological Association) · 2018-05-15

宁泌泰胶囊在下尿路症状中临床应用中国专家共识

中国中医药信息研究会(CIATCM,China Information Association For Traditional Chinese Medicine and Pharmacy) 男科分会 · 2017-09-30

2015 NICE临床指南：男性下尿路症状的评估和管理（CG97）

暂未更新 · 2015-06-01

拓展阅读

2018 CUA指南：男性下尿路症状/良性前列腺增生(更新版)

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2018-10-12

男性下尿路症状诊断和治疗中国专家共识

中华医学会男科学分会男性下尿路症状诊断和治疗中国专家共识编写组 · 2021-12-20

2022 EAU 指南：非神经源性男性 LUTS 的管理

欧洲泌尿外科学会(EAU,European Association of Urology) · 2022-03-04

2022 CUA指南：男性下尿路症状／良性前列腺增生(更新版)

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2022-08-01

《加拿大泌尿外科学会男性下尿路症状/良性前列腺增生指南更新》解读

暂未更新 · 2023-12-08